StressMarq and Gubra Generate 3D Whole-brain Imaging Model Depicting Alpha-synuclein
A collaboration between StressMarq Biosciences and Gubra has generated a 3D whole-brain light sheet fluorescence imaging model depicting alpha-synuclein pSer129+ aggregation in a mouse brain following injection with StressMarq’s alpha synuclein pre-formed fibrils.
StressMarq Biosciences, a market leader in the development and commercialization of unique fibrilized and oligomeric protein preparations for use in neurodegenerative disease research, collaborated with Gubra, a specialized high-end preclinical CRO and biotech company. Using StressMarq’s Alpha Synuclein Pre-formed Fibrils (catalog# SPR-324), Gubra generated a 3D whole-brain light sheet fluorescence imaging model depicting alpha-synuclein pSer129+ aggregation in a mouse brain.
StressMarq has developed a range of unique fibrilized and oligomeric protein preparations for use in neurodegenerative disease research, including Alpha Synuclein Pre-formed Fibrils (PFFs), which can be used to study alpha synuclein aggregation and pathology in vitro and in vivo. Gubra has expertise in high-resolution whole-brain 3D light sheet fluorescence imaging, which is a cutting-edge technique that allows visualization of large tissue volumes with minimal sample processing and high spatial resolution.
A novel model of alpha synuclein aggregation in the mouse brain
By combining these two technologies, StressMarq and Gubra have created a novel model of alpha synuclein aggregation in the mouse brain, which can be used to investigate the spatiotemporal dynamics of alpha synuclein pathology and its impact on neuronal connectivity and function. The model was generated by injecting StressMarq’s Alpha Synuclein Pre-formed Fibrils (catalog# SPR-324) into the striatum of mice, which is a brain region that is affected by Parkinson’s disease. Four weeks after injection, the mouse brains were imaged using Gubra’s whole-brain 3D light sheet fluorescence imaging system, which revealed widespread alpha-synuclein pSer129+ aggregation throughout the cortex and the ipsilateral substantia nigra pars compacta, which is the main source of dopaminergic neurons in the brain.
This model represents a significant advancement in the field of Parkinson’s disease research, as it allows for the visualization of alpha-synuclein aggregation at the whole-brain level, as well as the identification of the regions and pathways affected by the protein pathology. This could help to better understand the mechanisms and progression of Parkinson’s disease, as well as to evaluate potential therapeutic interventions.
About StressMarq
StressMarq is a market leader in the development and commercialization of a range of unique fibrilized and oligomeric protein preparations for use in neurodegenerative disease research, including proteins such as alpha synuclein, tau, amyloid beta, SOD1 and TTR. StressMarq’s strategic efforts are focused on expanding the breadth and depth of this product offering to assist researchers studying Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.
For more information please complete the quick contact form or visit: www.stressmarq.com
About Gubra
Gubra is a highly specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The combination of our advanced, high-end models and technologies ensures rapid turnaround time and high-quality data.
For more information please visit: www.gubra.dk
